8-K: Aquestive Therapeutics Resubmits Anaphylm NDA to FDA

Aquestive Therapeutics announced the resubmission of its New Drug Application (NDA) for Anaphylm (dibutepinephrine) sublingual film to the U.S. Food and Drug Administration (FDA), supported by positive study results.

Summary

• Aquestive Therapeutics has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Anaphylm (dibutepinephrine) sublingual film, intended for the treatment of Type I allergic reactions, including anaphylaxis.
• The resubmission follows a Complete Response Letter (CRL) received on January 30, 2026, and is supported by positive topline results from human factors and pharmacokinetic (PK) studies.
• These studies evaluated a revised packaging design and instructions for use, which significantly reduced median pouch-opening time from 17 seconds to 3 seconds.
• The company anticipates the FDA will classify the resubmission and establish a review timeline.
• Aquestive Therapeutics is also advancing its pipeline, including AQST-108 (epinephrine) topical gel for dermatological conditions.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating progress in regulatory matters and a strong commitment to bringing a potentially life-saving product to market.

Positives

• Successful resubmission of the Anaphylm NDA to the FDA, demonstrating progress in the regulatory process.
• Positive human factors study results showing a significant reduction in pouch-opening time (from 17 to 3 seconds), addressing a key concern from the FDA's CRL.
• Confirmatory PK study showed no protocol-defined use errors in the self-administration arm.
• Anaphylm is positioned as a needle-free, orally delivered epinephrine product, potentially addressing significant unmet needs in anaphylaxis treatment.
• The company has a diversified pipeline with other potential products like AQST-108 topical gel.
• Strong market potential for Anaphylm, with an estimated epinephrine market value projected to reach ~$2.03 billion by 2029.
• Positive patient preference survey results, with 96% of respondents preferring Anaphylm over a nasal spray in a hands-on survey.
• Proactive payer engagement and market access readiness plans are in place.

Negatives

• The FDA has not yet classified the resubmission, and the review timeline is uncertain.
• The FDA may not agree that the resubmission constitutes a complete response to the CRL.
• Potential for longer review periods if the FDA classifies the resubmission differently than anticipated.
• Risks associated with potential government shutdowns affecting FDA review timelines.
• The Anaphylm trade name is conditionally approved and subject to final FDA product approval.

Risks

• The FDA may determine that the NDA resubmission does not constitute a complete response to the CRL.
• The FDA may classify the resubmission differently than anticipated, leading to a longer review period.
• The FDA may not establish a review goal date within the anticipated timeframe.
• Preliminary, topline, interim, or summary study results may differ from final analyses or be interpreted differently by regulatory authorities.
• The FDA may disagree with the company's interpretation of study results or request additional information, analyses, or studies.
• Risks associated with addressing FDA comments and deficiencies in the NDA, potentially leading to lengthy reviews.
• Potential consideration of issues raised in citizen petitions by the FDA.
• Delays or changes in the timing, cost, or success of product development programs and clinical studies.

Future Outlook

The company is awaiting FDA classification and review timeline for the Anaphylm NDA resubmission. They anticipate potential international filings in Canada by the end of 2026 and in the EU in Q1 2027. The company is also advancing AQST-108 (epinephrine) topical gel for dermatological indications.

Management Comments

• "This resubmission reflects the rigor of our response to the FDA's Complete Response Letter, and we believe it addresses the items identified by the FDA in the Complete Response Letter."
• "The completed studies generated human factors, pharmacokinetic, and pharmacodynamic data supporting the revised packaging design and instructions for use, including reducing median pouch-opening time from 17 seconds to 3 seconds."
• "Our conviction in Anaphylm's potential has never been stronger. As we prepare for a focused, allergist-first launch, if approved, we are moving with urgency to bring Anaphylm to the patients who need it most."

Industry Context

StockSavvy.ai notes that the resubmission of the Anaphylm NDA is a critical step in a competitive market for anaphylaxis treatment. The focus on a needle-free, orally delivered option addresses known patient and caregiver barriers associated with current epinephrine auto-injectors, aligning with industry trends towards more patient-centric drug delivery systems.

Stakeholder Impact

• Shareholders: Positive development as it signifies progress towards potential product approval and future revenue generation.
• Patients: Potential for a new, needle-free treatment option for anaphylaxis, addressing convenience and administration barriers.
• Healthcare Providers: May offer an alternative to existing epinephrine auto-injectors, with a focus on ease of use and rapid administration.
• Payers: Will evaluate the clinical differentiation and value proposition of Anaphylm for reimbursement decisions.

Next Steps

• FDA review of the Anaphylm NDA resubmission.
• Potential classification of the resubmission and establishment of a review timeline by the FDA.
• Potential ex-US filings in Canada (end of 2026) and the EU (Q1 2027).
• Continued advancement of the AQST-108 topical gel program.

Key Dates

Recommendation

The resubmission is a positive step, but regulatory approval is not guaranteed, and the review timeline remains uncertain. While the product shows promise and addresses unmet needs, further clarity on FDA feedback and potential approval timelines is required before a more definitive recommendation can be made. The company's pipeline is also a factor, but Anaphylm's approval is the most immediate catalyst.

Keywords

Anaphylm, Anaphylaxis, Epinephrine, NDA Resubmission, FDA, Sublingual Film, Allergic Reactions, Pharmaceutical